Open tender · Germany · Pharmaceutical products
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)
In EnglishConclusion of a non-exclusive discount agreement under § 130a para. 8 SGB V for medicinal products with the active ingredient Denosumab Xgeva (ATC code according to WHO: M05BX04)
AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen
AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen in Germany is inviting bids for “Conclusion of a non-exclusive discount agreement under § 130a para. 8 SGB V for medicinal products with the active ingredient Denosumab Xgeva (ATC…”. Bids close on 31 July 2027, 23:58 CEST. askTender lists every requirement to qualify and checks whether your company meets them.
The work
Conclusion of non-exclusive discount agreements for the medicinal product Denosumab Xgeva (ATC-Code M05BX04) within an Open-House model.
Key facts
- Procedure
- Contract notice
Before you bid, askTender
Everything else is in your askTender account
askTender has broken this tender down into 4 requirements to qualify (2 on experience, 2 certifications and registrations) and the 2 documents a bidder must file.
- What it takes to qualify: every requirement, in the tender’s own words
- Whether your company qualifies: your profile checked against each requirement, showing what you have, what’s missing and how to close the gap
- The documents to file: a checklist, with draft declarations ready to sign
- A bid partner for any requirement you can’t meet alone
- The tender documents, ready to open
- Alerts for new tenders like this one
Public data: TED – Tenders Electronic Daily. © European Union, 1998–2026. Notices reused under Commission Decision 2011/833/EU. · Sources & licences